Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment.

NCT07547956 | Recruiting

• 1 other identifier: MS-376-2025
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to evaluate and compare the efficacy and safety of two different injectable agents combined with subcision for treating rolling acne scars. In this split-face clinical trial, each participant will receive subcision on both sides of the face. One side will then be treated with an injection of Polydeoxyribonucleotide (PDRN), while the other side will receive an injection of non-cross linked Hyaluronic acid (HA). The clinical outcomes and improvement in scar appearance will be assessed and compared between both treatments

Conditions

Atrophic Acne Scars

Keywords

subcision; PDRN; Hyakuronic acid; atrophic acne scars

Outcome Measures

Primary Outcomes (2)

• Percent change in atrophic acne scar topography

  Percent change from baseline in acne scar area, volume, and maximum depth as assessed by Antera 3D image analysis

  Baseline, Week 12, and Week 24 (3 months after last injection).

• Change in Goodman and Baron Quantitative Score.

  Mean change in the Goodman and Baron Quantitative Score for rolling acne scars. The score categorizes severity as: Mild (1 to 6), Moderate (7 to 15), and Severe (16 or above)

  Baseline, Week 12, and Week 24 (3 months after last injection).

Secondary Outcomes (9)

• Patient and Observer Scar Assessment Scale (POSAS) - Observer Scale

  Baseline, Week 12, and Week 24 (3 months after last injection).

• Patient and Observer Scar Assessment Scale (POSAS) - Patient Scale

  Baseline, Week 12, and Week 24 (3 months after last injection)

• Proportion of patients with clinically significant POSAS improvement

  Week 12 and Week 24

• Proportion of patients with \ge30% improvement in Goodman and Baron score

  Week 12 and Week 24.

• Change in total atrophic acne scar counts

  Baseline, Week 12, and Week 24.

Study Arms (1)

split-face treatment arm

EXPERIMENTAL

Each participant will receive two different treatments: one side of the face will be treated with subcision followed by injection of polydeoxyribonucleotide, while the contralateral side will be treated wit subcision followed by injection of non-cross linked hyaluronic acid

Procedure: subcision with PDRN vs HA injection

Interventions

subcision with PDRN vs HA injection PROCEDURE

Each participant will receive two different treatments on each side of the face. One side will be treated with subcision followed by PDRN injection, while the other side will be treated with subcision followed by non-cross linked Hyaluronic Acid injection. Clinical assessment and 3D image analysis will be used for evaluation.

split-face treatment arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Moderate to severe mainly rolling acne scars per validated scale (Goodman \& Baron Grade 3-4)
• Scars must be bilaterally distributed, allowing for split-face comparison
• Stable acne (no active nodulocystic lesions, pustules, or recent outbreaks for ≥6 months)
• No scar treatments (e.g., fillers, laser, microneedling) within the past 12 months
• All skin types.
• Both genders above 18 years old

You may not qualify if:

• Systemic retinoid treatment within the last 6 months
• Active inflammatory acne
• Lidocaine sensitivity
• Pregnancy and lactation
• Severe systemic illness or malignancy
• Use of anticoagulant or antiplatelet medications (unless cleared) Use of oral isotretinoin within the past 6 month
• Herpes libialis, bacterial infection, other infections such as HBV, HCV or HIV
• Tendency to keloid formation
• Allergy to fish and salmon

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Cairo University, Dermatology Department

Cairo, Egypt

RECRUITING

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MSc Candidate in Dermatology

Study Record Dates

• First Submitted: April 17, 2026
• First Posted: April 23, 2026
• Study Start: October 20, 2025
• Primary Completion: June 20, 2026
• Study Completion: July 20, 2026
• Last Updated: May 18, 2026

Record last verified: 2026-05

Locations

EG (1)